Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 17/20 | 1.00 |
| ▸ | DRD2 | P14416 | 16/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29448456 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4 | |
| SCHEMBL10896624 | 0.83 | DRD2 (1.00) | DRD3DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL10898263 | 0.82 | DRD2 (0.97) | DRD3DRD2DRD4 | |
| SCHEMBL10976331 | 0.79 | DRD2 (1.00) | DRD3DRD2DRD4 | |
| SCHEMBL7854627 | 0.78 | DRD3 (0.67) | DRD3DRD2 | |
| SCHEMBL7860144 | 0.78 | DRD3 (0.66) | DRD3DRD2DRD4 | |
| SCHEMBL9757621 | 0.76 | DRD2 (0.83) | DRD3DRD2DRD4 | |
| SCHEMBL7860284 | 0.76 | DRD3 (0.63) | DRD3DRD2 | |
| SCHEMBL11496079 | 0.75 | DRD2 (0.82) | DRD3DRD2DRD4 | |
| SCHEMBL7864930 | 0.74 | DRD3 (0.61) | DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220233475-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | UNIV DREXEL (US) | 2022-07-28 | — | — | US | disclosed |
| US-11266612-B2 | D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease | DREXEL UNIVERSITY (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200390728-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | UNIV DREXEL (US) | 2020-12-17 | — | — | US | disclosed |
| US-10543180-B2 | D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease | DREXEL UNIVERSITY (US) | 2020-01-28 | — | — | US | disclosed |
| US-20170246128-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | UNIV DREXEL (US) | 2017-08-31 | — | — | US | disclosed |
| US-9675565-B2 | D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | DREXEL UNIVERSITY (US) | 2017-06-13 | — | — | US | disclosed |
| US-9289400-B2 | D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | DREXEL UNIVERSITY (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2439203-B1 | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBVIE DEUTSCHLAND (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-20140228380-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | UNIVERSITY OF MEDICINE AND DENTISTRY NEW JERSEY MEDICAL SCHOOL (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228355-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | UNIVERSITY OF MEDICINE AND DENTISTRY NEW JERSEY MEDICAL SCHOOL (US) | 2014-08-14 | — | — | US | disclosed |
| EP-1812416-B1 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2013-08-21 | — | — | EP | disclosed |
| EP-2603215-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | Philadelphia Health and Education Corporation (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012021629-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390728-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | DRD3, PARK7, SLC6A3 | DRD3 1/4885DRD2 4/4885DRD4 15/4885 |
| US-10543180-B2 | D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease | DRD3, PARK7, SLC6A3 | DRD3 1/4885DRD2 4/4885DRD4 13/4885 |
| US-11266612-B2 | D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease | DRD3, PARK7, SLC6A3 | DRD3 1/4885DRD2 4/4885DRD4 13/4885 |
| US-20220233475-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | DRD3, PARK7, SLC6A3 | DRD3 1/4885DRD2 4/4885DRD4 15/4885 |
| US-20140228380-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | DRD3, PARK7, SLC6A3 | DRD3 1/4885DRD2 4/4885DRD4 15/4885 |
| US-20170246128-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | DRD3, PARK7, SLC6A3 | DRD3 1/4885DRD2 4/4885DRD4 15/4885 |
| US-20140228355-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | DRD3, PARK7, SLC6A3 | DRD3 1/4885DRD2 4/4885DRD4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.